We are live on ! Find out more
PRAH

PRA Health Sciences, Inc.
PRAH

Delisted

PRAH was delisted on the 30th of June, 2021.

236 hedge funds and large institutions have $4.66B invested in PRA Health Sciences, Inc. in 2017 Q2 according to their latest regulatory filings, with 36 funds opening new positions, 88 increasing their positions, 93 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more funds holding in top 10

Funds holding in top 10: 37 (+4)

29% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 28

15% more capital invested

Capital invested by funds: $4.06B → $4.66B (+$602M)

3% more funds holding

Funds holding: 229236 (+7)

5% less repeat investments, than reductions

Existing positions increased: 88 | Existing positions reduced: 93

67% less call options, than puts

Call options by funds: $4.59M | Put options by funds: $14.1M

Holders
236
Holders Change
+7
Holders Change %
+3.06%
% of All Funds
5.88%
Holding in Top 10
7
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+133.33%
% of All Funds
0.17%
New
36
Increased
88
Reduced
93
Closed
28
Calls
$4.59M
Puts
$14.1M
Net Calls
-$9.5M
Net Calls Change
+$35K
Name Holding Trade Value Shares
Change
Change in
Stake
FDCDDQ
126
Federation des caisses Desjardins du Quebec
Quebec, Canada
$2.02M -$355K -5,125 -16%
MLICM
127
Metropolitan Life Insurance Company (MetLife)
New York
$1.97M +$622K +8,968 +52%
LCG
128
Lisanti Capital Growth
New York
$1.93M +$143K +2,070 +9%
Point72 Asset Management
129
Point72 Asset Management
Connecticut
$1.88M -$16.8M -242,913 -91%
AIG
130
American International Group
New York
$1.8M +$635K +9,157 +61%
SAM
131
Sawgrass Asset Management
Florida
$1.74M -$15.9K -230 -1%
UBS AM
132
UBS AM
Illinois
$1.65M +$90.3K +1,303 +6%
Fuller & Thaler Asset Management
133
Fuller & Thaler Asset Management
California
$1.58M +$783K +11,300 +115%
AIA
134
Avalon Investment & Advisory
Texas
$1.58M +$187K +2,695 +15%
AL
135
Airain Ltd
Guernsey
$1.47M -$871K -12,565 -39%
CIC
136
Carnegie Investment Counsel
Ohio
$1.41M +$1.08M +15,630 +479%
SO
137
STRS Ohio
Ohio
$1.39M +$194K +2,800 +18%
VOYA Investment Management
138
VOYA Investment Management
Georgia
$1.36M +$585K +8,445 +87%
DCM
139
Dupont Capital Management
Delaware
$1.34M -$2.92M -42,108 -70%
Cambridge Investment Research Advisors
140
Cambridge Investment Research Advisors
Iowa
$1.33M +$1.23M +17,758 New
HCMT
141
Highland Capital Management (Texas)
Texas
$1.3M -$910K -13,120 -43%
Citigroup
142
Citigroup
New York
$1.3M +$764K +11,028 +175%
TC
143
Telemus Capital
Michigan
$1.27M -$208K -3,000 -15%
CG
144
Clinton Group
New York
$1.21M +$1.11M +16,069 New
AAMU
145
AEGON Asset Management (UK)
United Kingdom
$1.18M -$425K -6,136 -28%
EAM
146
EULAV Asset Management
Florida
$1.14M -$277K -4,000 -21%
SEI Investments
147
SEI Investments
Pennsylvania
$1.1M +$47.8K +690 +5%
Tudor Investment Corp
148
Tudor Investment Corp
Connecticut
$1.08M +$281K +4,056 +39%
IA
149
Icon Advisers
Colorado
$1.07M -$485K -7,000 -33%
RJA
150
Raymond James & Associates
Florida
$1.05M +$285K +4,113 +42%

PRAH Hedge Fund Activity: Q2 2017 in Review

236 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in PRA Health Sciences, Inc. (PRAH) for Q2 2017, worth a combined $4.66B — up 15% from $4.06B a quarter earlier.

Buyers outnumbered sellers: 36 funds opened new PRAH positions and 28 closed out — a net gain of 8 holders — while 88 added to existing stakes and 93 trimmed.

The largest buyer was Capital Research Global Investors, adding an estimated $115M. The largest seller was Marshall Wace North America, cutting an estimated $62.1M.

  • 236 institutional investors held PRA Health Sciences, Inc. (PRAH) as of Q2 2017, up from 229 in Q1 2017.
  • Funds reported $4.66B of PRA Health Sciences, Inc. stock for Q2 2017, up 15% quarter-over-quarter.
  • 36 funds opened new PRA Health Sciences, Inc. positions in Q2 2017 and 28 closed out, a net change of +8 holders.
  • The largest PRA Health Sciences, Inc. buyer in Q2 2017 was Capital Research Global Investors, an estimated $115M added.
  • The largest PRA Health Sciences, Inc. seller in Q2 2017 was Marshall Wace North America, an estimated $62.1M sold.

Based on aggregated 13F filings for Q2 2017.